Your browser doesn't support javascript.
loading
Efficacy and safety of the long-acting fusion inhibitor albuvirtide in antiretroviral-experienced adults with human immunodeficiency virus-1: interim analysis of the randomized, controlled, phase 3, non-inferiority TALENT study / 中华医学杂志(英文版)
Chinese Medical Journal ; (24): 2919-2927, 2020.
Article in English | WPRIM | ID: wpr-877929
ABSTRACT
BACKGROUND@#Albuvirtide is a once-weekly injectable human immunodeficiency virus (HIV)-1 fusion inhibitor. We present interim data for a phase 3 trial assessing the safety and efficacy of albuvirtide plus lopinavir-ritonavir in HIV-1-infected adults already treated with antiretroviral drugs.@*METHODS@#We carried out a 48-week, randomized, controlled, open-label non-inferiority trial at 12 sites in China. Adults on the World Health Organization (WHO)-recommended first-line treatment for >6 months with a plasma viral load >1000 copies/mL were enrolled and randomly assigned (11) to receive albuvirtide (once weekly) plus ritonavir-boosted lopinavir (ABT group) or the WHO-recommended second-line treatment (NRTI group). The primary endpoint was the proportion of patients with a plasma viral load below 50 copies/mL at 48 weeks. Non-inferiority was prespecified with a margin of 12%.@*RESULTS@#At the time of analysis, week 24 data were available for 83 and 92 patients, and week 48 data were available for 46 and 50 patients in the albuvirtide and NRTI groups, respectively. At 48 weeks, 80.4% of patients in the ABT group and 66.0% of those in the NRTI group had HIV-1 RNA levels below 50 copies/mL, meeting the criteria for non-inferiority. For the per-protocol population, the superiority of albuvirtide over NRTI was demonstrated. The frequency of grade 3 to 4 adverse events was similar in the two groups; the most common adverse events were diarrhea, upper respiratory tract infections, and grade 3 to 4 increases in triglyceride concentration. Renal function was significantly more impaired at 12 weeks in the patients of the NRTI group who received tenofovir disoproxil fumarate than in those of the ABT group.@*CONCLUSIONS@#The TALENT study is the first phase 3 trial of an injectable long-acting HIV drug. This interim analysis indicates that once-weekly albuvirtide in combination with ritonavir-boosted lopinavir is well tolerated and non-inferior to the WHO-recommended second-line regimen in patients with first-line treatment failure.@*TRIAL REGISTRATION@#ClinicalTrials.gov Identifier NCT02369965; https//www.clinicaltrials.gov.Chinese Clinical Trial Registry No. ChiCTR-TRC-14004276; http//www.chictr.org.cn/enindex.aspx.
Subject(s)
Full text: Available Index: WPRIM (Western Pacific) Main subject: Peptides / HIV Infections / China / HIV-1 / Treatment Outcome / Ritonavir / Anti-HIV Agents / Viral Load / Antiretroviral Therapy, Highly Active / Drug Therapy, Combination Type of study: Controlled clinical trial / Practice guideline / Prognostic study Limits: Adult / Humans Country/Region as subject: Asia Language: English Journal: Chinese Medical Journal Year: 2020 Type: Article

Similar

MEDLINE

...
LILACS

LIS

Full text: Available Index: WPRIM (Western Pacific) Main subject: Peptides / HIV Infections / China / HIV-1 / Treatment Outcome / Ritonavir / Anti-HIV Agents / Viral Load / Antiretroviral Therapy, Highly Active / Drug Therapy, Combination Type of study: Controlled clinical trial / Practice guideline / Prognostic study Limits: Adult / Humans Country/Region as subject: Asia Language: English Journal: Chinese Medical Journal Year: 2020 Type: Article